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significantly increasing with their initial disease severity. Amount of db loss per
year were in line with previously published prospective studies.
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OBJECTIVES: The objective of this study was to summarize epidemiology, disease
burden, symptomatology, treatment pattern, and quality of life in macular degen-
eration (MD) in the Korean population through a systematic literature review.
METHODS: Literature searches were conducted through Korean databases(RISS,
KMBase, KoreaMed, NDSL, National Assembly Library), national statistics portals
and ophthalmology journals for the period to April 2011, using macular degener-
ation as a keyword. Publications were selected according to pre-defined selection
criteria. RESULTS: Forty-three studies were identified and included in the review.
Most (40) described clinical characteristics and treatment pattern. 4 described ep-
idemiology and 2 focused on quality of life. No study estimated economic burden.
In summary, 1) MD characterizes exudative form, subretinal neovascularization or
retinal pigment epithelial detachment, and equal distribution of circular and geo-
graphic atrophy; 2) MD is a major reason of low vision/visual impairment; 3) Drug
therapy such as bevacizumab or ranibizumab presents effects on decrease of cen-
tral macular thickness and preservation of visual acuity, but optimized patients
have to be identified. Photodynamic therapy is relatively safe, and pneumatic dis-
placement or radiation therapy is somehow effective on visual acuity even though
being a risk of vision loss. Concurrent drug and non-drug therapies have been tried
as well clinically; 4) Prevalence of MD is higher in elderly over 65 years with 13.3%
rate and higher proportion of exudative form than western countries; and 5) Qual-
ity of life is decreased in patients with MD or low vision. CONCLUSIONS: This study
describes lack of local information especially disease burden and quality of life. In
the era growing sharply aging population, prevent and treat MD are crucial for
preserving vision and improving quality of life. Therefore future studies are
needed.
PSS7
PREVALENCE ASSESSMENT OF DIABETIC MACULAR EDEMA WITH VISUAL
IMPAIRMENT IN SPAIN: A PREVAIL STUDY
Andres I1, Balañá M1, Gallagher M2, Riera M3, Pareja A4, Barrot J5, Orozco D6, Roura M1
1Medical Department. Novartis Farmacéutica S.A., Barcelona, Barcelona, Spain, 2Novartis
Pharma A.G., Basel, -, Switzerland, 3Market Access Department. Novartis Farmacéutica S.A.,
Barcelona, Barcelona, Spain, 4Hospital Universitario Insular de Gran Canaria, Las Palmas de
Gran Canaria, ., Spain, 5Centro Atención Primaria, Salt, Girona, Spain, 6C.S. Petrer II, Alicante, .,
Spain
OBJECTIVES: Diabetic macular edema (DME) is the main cause of visual impair-
ment (VI) in diabetic patients. The prevalence of DME is estimated to be 5.4% in
Europe, but there is no observational evidence currently available. The objective
was to determinate the prevalence of DME and DME with VI from Belgium, France,
Germany, Italy, The Netherlands, Spain and UK, in an epidemiological study. Re-
ported here are the results from Spain. METHODS: Patients with diabetes mellitus
types 1 and 2 (DM1 and DM2) were consecutively recruited by General Practitioners
(GPs) across Spain. Diagnosis and severity of DME, related VI, sociodemographics,
general and ophthalmic comorbidities, HbA1c, antidiabetic and DME treatment
were documented. Patients with retinitis pigmentosa, epiretinal membrane, or
active uveitis were excluded from the calculation of VI due to DME. RESULTS: A
total of 26 GPs recruited 445 eligible patients (38 DM1, 411 DM2) from July 2010 to
April 2011, 51.2% male, mean (SD) age of 66.2 (12.8) years, 37.2% smokers or ex-
smokers. Patients with DME diagnosis showed a longer length of time since onset
of diabetes (14.55 y vs 9.64). The prevalence of DME was estimated to be 4% (18/445
patients) (95%CI 2.2-5.8%) and VI due to DME was 2% (9/445) (95%CI 0.7-3.3%). Poor
diabetic control (HbA1c 7%) was reported in 219 (48.8%) of all patients, being
higher in those with DME (66.7%). Ocular comorbidities, such as cataract or glau-
coma, were present in 17 (94.4%) DME patients. 15 (83.3%) patients received DME
treatment, mainly laser photocoagulation (77.8%), alone or in combination with
vitrectomy and/or pharmacological treatment. CONCLUSIONS: ME affects 4% of
the diabetic patients in Spain, and 2% of them suffer VI due to DME. Results suggest
that poor diabetic control and long time since diabetis onset are associated with
development of DME. This study was sponsored by Novartis Pharma AG.
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OBJECTIVES: Cutaneous malignant melanoma (CMM) is an uncommon yet aggres-
sive form of skin cancer. In 2008, CMM was found to be the sixth most common
cancer in the UK. The aim of this review was to identify the incidence of advanced
CMM in the UK (UK). The definition of advanced CMM was stage IIIc and stage IV
disease in affected patients. METHODS: Multiple sources including the Cochrane
Library, MEDLINE, EMBASE and CINAHL were searched between December 2010
and March 2011. Searches were also conducted by scanning the websites of the
Office of National Statistics, Cancer Research UK as well as the Welsh Cancer In-
telligence and Surveillance Unit. A narrative synthesis was undertaken due to
heterogeneity in included studies. RESULTS: Of the three included studies, 2 were
conducted in Scotland while one was undertaken in the East Anglia region of Eng-
land. Although all patients had a confirmed diagnosis of CMM, variations in staging
methods and unclear or insufficient reporting made it challenging to identify pa-
tients with stage IIIc and stage IV disease. Both studies undertaken in Scotland at
different periods reported that 2% of all melanoma patients had advanced CMM at
the time of diagnosis. However, the definitions of advanced CMM were not similar
in each study. The incidence of stage IV CMM reported in 3,971 patients from East
Anglia decreased from 0.42 to 0.13 per 100,000 population per year between 1991
and 2004.CONCLUSIONS:This review highlighted the lack of, and need for primary
studies to estimate the incidence of advanced CMM in the UK. In order to examine
trends across UK as well as identify patients for targeted treatment, we suggest that
researchers must clearly define this sub-group in future studies.
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OBJECTIVES: Age-Related Macular Degeneration (AMD) is a disorder of the central
area of the retina resulting in a significant loss of visual acuity. AMD is the leading
cause of incurable blindness and visual impairment in industrialized countries.
Consequently AMD leads to decrease of Quality of Life (QoL) and increased health
care costs. For the The Netherlands no information on the burden of AMD was
available. The main aim of this study was to assess the burden of AMD patients in
the The Netherlands in terms of health care costs and QoL from a societal
perspective. METHODS: AMD cost parameters were identified and the ‘AMD cost
and impact questionnaire’ was developed. Members of the Dutch Macular Degen-
eration Patient Organization with a disease severity ranging from normal vision to
legally blind were invited to enter the study during regional meetings. The EuroQol
5D was used for measuring QoL. Data on resource use and QoL were collected
through telephone interviews. RESULTS: Seventy-five patients completed the
questionnaire. The average total annual cost for AMD was €5651 per person (95% CI:
4252 - 7051). Home help was the major cost component (€2507 p.p.). Total costs
were significantly higher for individuals with more severe AMD and the QoL sig-
nificantly lower for individuals with more severe AMD (P0.05). The average utility
of AMD was 0.792 (95% CI: 0.771-0.812) significantly lower than the average 50
Dutch population (0.850). The respondents reported ‘usual activities’ as the area
with the most problems. CONCLUSIONS: Increased visual impairment leads to
significantly higher annual costs and lower overall QoL.
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OBJECTIVES: In glaucoma patients, the long term use of prostaglandin eye drops
containing benzalkonium chloride (BAK) increases the risk of developing an ocular
surface disease (OSD). Polyquad® preserved prostaglandins are now available,
among which travoprost proved similar in efficacy and safety compared to BAK-
preserved formulations. We aimed to estimate the impact of Polyquad® instead of
BAK on glaucoma management cost.METHODS:A Markov microsimulation model
was developed in TreeAge, including 5 health states corresponding to 4 treatment
lines plus death, in representative, treatment-naive patients at different OHT/glau-
coma stages. The sequence travoprost-travoprosttimolol fixed combination pre-
served with Polyquad® was compared to BAK-preserved latanoprost-
latanoprosttimolol (LAT) and bimatoprost-bimatoprosttimolol (BIM). The
model events were: onset of OSD (risk factors: age, sex, BAK exposure; sources: US
incidence study [Moss 2005], Erb 2008), need for treatment change including sur-
gery/laser (risk factors: treatment line, disease stage, OSD presence, BAK exposure;
sources: persistence studies in UK GPRD [Lafuma 2007] and US claims database
[Schmier 2010]), and disease progression (risk factors: treatment line, OSD severity,
non-compliance; sources: large prospective studies in OHT/glaucoma). Costs data
came from a German observational study in OHT/glaucoma with 5-year retrospec-
tive collection of medical resources used (Statutory Health Insurance perspective
patient co-payments; 2011 drug costs, other costs 2010). The 95% confidence inter-
vals came from a probabilistic sensitivity analysis. RESULTS: After 10 years, the
total management cost in the travoprost with Polyquad® arm was €4677 [4378;
5013] compared to €5196 [4904;5482] with LAT and €5342 [5069;5664] with BIM. More
patients required eye surgery/laser procedures with BAK-preserved sequences
(LAT: 4.7% [3.2;6.4%], BIM: 6.0% [4.0;8.3%]) compared to travoprost with Polyquad®
(1.8% [0.9;2.9%]). CONCLUSIONS: At 10 years, prostaglandin treatment with Poly-
quad® is expected to reduce the cost of glaucoma treatment by 10-15% from both
individual and societal perspectives, and have lower surgery/laser rates compared
to BAK-preserved treatments.
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OBJECTIVES: To evaluate and comparate the efficacy, safety and cost of the bev-
acizumab and ranibizumab intravitreous injections for the treatment of age related
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